Study of an investigational drug for non-obstructive hypertrophic cardiomyopathy
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-obstructive hypertrophic cardiomyopathy (a thickened heart muscle that does not block blood flow).
- You are on a stable treatment plan recommended by your doctor for this condition.
- Your symptoms are in class II or III, meaning you feel symptoms with mild or moderate activity.
- You have a test result showing your heart is under stress (NT-proBNP > 300 pg/mL).
- Your weight is between 50 and 100 kg and your body mass index is 40 or less.
- Your kidneys are working well enough, and you are not pregnant and agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
This study follows people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, to learn more about how it affects them in real life. It may help doctors better understand and manage the condition.
This trial tests whether a personalized exercise program can safely improve fitness and daily activity for people with hypertrophic cardiomyopathy (a heart muscle condition). You would work with experts to build a routine that fits your needs and current health.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
This study tests an experimental medication called Aom0304 for adults with symptomatic hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick). The goal is to see if it helps reduce symptoms and improve heart function.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Hear when a new Nonobstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.